Recruitment of clinical research volunteers (lung cancer)
The Hong Kong United Oncology Centre is currently conducting an international Phase III clinical trial. If you are a patient with locally advanced, unresectable, or metastatic HER2-overexpressing non-squamous non-small cell lung cancer with PD-L1 TPS < 50%, please contact us. We will conduct an initial assessment to determine if you meet the eligibility criteria for this clinical trial. Medication and imaging scan costs are fully covered. However, patients must understand the purpose of the study and the potential risks involved.
Research name
A phase III, multicenter, randomized, open-label trial comparing trastuzumab deruxtecan in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab as first-line treatment for patients with locally advanced unresectable or metastatic HER2-overexpressing non-squamous non-small cell lung cancer with PD-L1 TPS <50%.
A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Platinum-based Chemotherapy in Combination with Pembrolizumab, as First-line Therapy in Participants with Locally Advanced Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer.
ClinicalTrials.gov Identifier: NCT06899126 (view detailed research materials)
Patient eligibility
- Patients with locally advanced unresectable or metastatic non-squamous non-small cell lung cancer that is HER2-overexpressing and has a PD-L1 TPS <50%.
Patient with Locally Advanced Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer
Research remuneration
- Related treatment drugs, image scans and doctor's consultations are free of charge
Research process
If you are eligible to participate in this study, you will use the following treatment options：
- Trastuzumab Deruxtecan (T-DXd) combined with immunotherapy (Pembrolizumab)
Trastuzumab Deruxtecan (T-DXd) with Pembrolizumab - Platinum-based chemotherapy combined with immunotherapy (Pembrolizumab)
Platinum-based chemotherapy with Pembrolizumab
Related risks
During the study, you may experience discomfort and risks associated with treatment with Trastuzumab Deruxtecan (T-DXd) in combination with immunotherapy or platinum-based chemotherapy in combination with immunotherapy. The discomfort and risks may vary from person to person.
Contact method
Interested participants can contact us through the following methods for further understanding：
- WhatsApp：5518 2992
- Telephone：+852 2386 8002
- Email：Enquiry@hkuoc.hk
- WeChat: hkuoc23868002
Related resources
Inquire about more research projects：Clinical Research Page of the United Cancer Centre of Hong Kong
Learn more about non-small cell lung cancer:Hong Kong Hospital Authority-Lung Cancer Information
Research sponsor
Daiichi Sankyo, Inc.